Health Affairs

Health Affairs, 25, no. 2 (2006): 313-324 doi: 10.1377/hlthaff.25.2.313 © 2006 by Project HOPE	New Online   Getting Health Reform Done   After the State of the Union   Incremental Reform   E-Health in Developing World   Most-Read Articles in 2009

This Article Figures Only Full Text (HTML) Reprint (PDF) Technical Appendix Media/Policy Briefing Interview with lead author Submit a response to this article Comments: View responses Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Ridley, D. B. Articles by Moe, J. L. Search for Related Content PubMed PubMed Citation Articles by Ridley, D. B. Articles by Moe, J. L. Related Collections Health Promotion/Disease Prevention Health Reform International Issues Legal/Regulatory Issues Business Of Health Pharmaceuticals Public Health Research And Technology Health Spending Consumer Issues Related Blog Posts

Drugs/Vaccines

Developing Drugs For Developing Countries

David B. Ridley, Henry G. Grabowski and Jeffrey L. Moe

Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.

                      What's this?

Related Blog Posts:

This article has been cited by other articles:

				P. Musgrove and P. J. Hotez Turning Neglected Tropical Diseases Into Forgotten Maladies Health Aff., November 1, 2009; 28(6): 1691 - 1706. [Abstract] [Full Text] [PDF]

				J. Sonderholm A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs Public Health Ethics, July 3, 2009; (2009) php017v1. [Abstract] [Full Text] [PDF]

				J. Moe, H. Grabowski, D. Ridley, and A. S. Kesselheim FDA Review Vouchers N. Engl. J. Med., February 19, 2009; 360(8): 837 - 838. [Full Text] [PDF]

				A. S. Kesselheim Drug Development for Neglected Diseases -- The Trouble with FDA Review Vouchers N. Engl. J. Med., November 6, 2008; 359(19): 1981 - 1983. [Full Text] [PDF]

				M. Ravvin Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions Public Health Ethics, July 1, 2008; 1(2): 110 - 123. [Abstract] [Full Text] [PDF]

				M. K. Kyle and D. B. Ridley Would Greater Transparency And Uniformity Of Health Care Prices Benefit Poor Patients? Health Aff., September 1, 2007; 26(5): 1384 - 1391. [Abstract] [Full Text] [PDF]

				J. Fisher Wilson Alterations in processes and priorities needed for new drug development. Ann Intern Med, November 21, 2006; 145(10): 793 - 796. [Full Text] [PDF]

Comments: